Generate Biomedicines is a technology company.
Generate Biomedicines has raised $640.0M across 2 funding rounds.
Generate Biomedicines has raised $640.0M in total across 2 funding rounds.
Generate Biomedicines has raised $640.0M in total across 2 funding rounds.
Generate Biomedicines's investors include Alchemy Ventures, Alumni Ventures, Craft Ventures, Flagship Pioneering, Flagship Ventures, Gigascale Capital, iGlobe Partners, Menlo Ventures, Morgan Creek Capital Management, Multicoin Capital, Oak HC/FT, Pareto Holdings.
Generate:Biomedicines is a biotechnology company pioneering Generative Biology™, an AI-driven platform that uses machine learning to design and optimize novel proteins for therapeutics, targeting immunology, oncology, and infectious diseases.[1][2][3] The company builds protein-based medicines like antibodies, peptides, enzymes, and antibody-drug conjugates (ADCs), serving patients with intractable diseases by solving the inefficiencies of traditional trial-and-error drug discovery through de novo protein generation and rapid optimization for affinity, immunogenicity, and manufacturability.[1][6] It has demonstrated growth momentum with a $273 million Series C in 2023—the largest biotech Series C that year—over 42,000 proteins generated and tested, first-in-human trials for GB-0669 (SARS-CoV-2 antibody), and partnerships with Amgen and Novartis across multiple programs.[1][3][8]
Headquartered in Cambridge, Massachusetts, with 140k+ square feet in facilities, Generate operates at the intersection of machine learning, biological engineering, and medicine, backed by Flagship Pioneering.[1][2][3]
Generate:Biomedicines was founded in 2018 by Molly Gibson (computational and systems biology expert) and Gevorg Grigoryan (Chief Technology Officer), with support from Flagship Pioneering, to apply data-driven machine learning for decoding protein sequence-function relationships and creating novel therapeutics.[1][2][5] The idea emerged from replacing inefficient trial-and-error methods with generative models trained on millions of proteins, exemplified by their rapid 2020 response generating SARS-CoV-2 antibodies.[1][5]
Early traction included proving the platform's ability to generate antibodies and peptides against a dozen targets, outperforming traditional methods.[5] In 2021, Mike Nally (ex-Merck) became CEO, scaling infrastructure and collaborations; by 2023, funding fueled clinical trials and a 17-program pipeline.[1]
Generate rides the AI-in-biotech wave, merging machine learning with biological engineering to program biology like software, addressing R&D productivity crises where traditional discovery fails 90%+ of targets.[2][3][6][9] Timing aligns with explosive growth in generative AI (post-ChatGPT) applied to proteins, plus post-pandemic demand for fast antivirals and personalized meds amid rising chronic diseases.[1][5]
Market forces favor it: biotech funding rebound, AI hardware advances enabling massive protein datasets, and pharma's shift to partnerships for tech platforms.[1][8] Generate influences the ecosystem by democratizing biotherapeutics—licensing tech to partners, expanding pipelines, and proving AI can slash discovery timelines from years to months, inspiring competitors like Absci or Isomorphic Labs.[3][5][8]
Generate:Biomedicines is poised to lead AI-native drug discovery, with clinical readouts from GB-0669 and GB-0895 trials driving milestones, pipeline expansion (17+ programs), and deeper Amgen/Novartis deals.[1][6][8] Trends like multimodal AI, single-cell data integration, and regulatory nods for AI-designed drugs (e.g., FDA pilots) will accelerate its platform, potentially yielding first approvals by 2027-2028.
Its influence may evolve from pioneer to standard-setter, powering an era of "programmable medicines" that cure intractable diseases, fundamentally reshaping biotech from empirical to engineered—echoing its mission to expand biology's possibilities.[2][3]
Generate Biomedicines has raised $640.0M across 2 funding rounds. Most recently, it raised $270.0M Series C in September 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2023 | $270.0M Series C | Alchemy Ventures, Alumni Ventures, Craft Ventures, Flagship Pioneering, Flagship Ventures, Gigascale Capital, iGlobe Partners, Menlo Ventures, Morgan Creek Capital Management, Multicoin Capital, Oak HC/FT, Pareto Holdings, Picus Capital, Ripio Ventures, Stellar Capital, Upload Ventures, Tony Xu | |
| Nov 1, 2021 | $370.0M Series B | Alumni Ventures, Flagship Pioneering, Flagship Ventures |